EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Efficacy of prophylactic adoption of recombinant human granulocyte colony-stimulating factor in advanced lung cancer patients after chemotherapy

Dada Yao, Huaqiang Zhou, Qichen Chen

Tissue and Cell · 2026

DOI: 10.1016/j.tice.2025.103288 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Tissue and Cell, 2026. Verfasst von Dada Yao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, The Third People's Hospital of Yuhang District, Hangzhou, Zhejiang 311115, China. Electronic address: YAOcr2020@163.c…. Hauptthemen laut MEDLINE: Granulocyte Colony-Stimulating Factor, Lung Neoplasms, Recombinant Proteins. Die Arbeit nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Lung cancer (LC) is a prevalent and lethal malignancy with limited treatments for advanced stages. The aim was to investigate the outcome of prophylactic adoption of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in advanced LC patients on the basis of concurrent chemoradiotherapy. METHODS: A total of 150 patients with advanced LC who received concurrent chemoradiotherapy at The Third People's Hospital of Yuhang District between April 2023 and April 2025 were randomly assigned to two groups: an observation group (AG) and a control group (BG). Subjects were treated with platinum-based doublet chemotherapy combined with intensity-modulated conformal radiotherapy. AG received prophylactic rhG-CSF administration within 24-72 h after chemotherapy. The white blood cell (WBC) count, neutrophil (NEU) count, immune function indicators, inflammatory factor levels, and clinical efficacy were compared. RESULTS: Following treatment, the WBC and NEU counts in AG were higher as against BG; CD4+ T cells was higher, while CD8+ T cells, CD3+PD-1 T cells, etc., were lower in AG as against BG; IL-10, IL-6, and TNF-α in AG were lower as against BG; objective response rate (ORR) (44.0 %) and disease control rate (DCR) (88.0 %) in AG were elevated as against BG (26.7 %, 64.0 %) (P < 0.05). CONCLUSION: Prophylactic adoption of rhG-CSF during concurrent chemoradiotherapy in advanced LC patients can protect hematopoietic function, regulate immune balance, reduce inflammatory response, and improve clinical efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Granulocyte Colony-Stimulating FactorLung NeoplasmsRecombinant ProteinsHumansMaleFemaleMiddle AgedAgedAdultChemoradiotherapyTreatment Outcome

Stichwörter der Autor:innen

Advanced lung cancerConcurrent chemoradiotherapyImmune functionInflammatory factorsRecombinant human granulocyte colony-stimulating factor

Substanzen

Granulocyte Colony-Stimulating FactorRecombinant Proteins

Autor:innen und Institutionen

  • Department of Medical Oncology, The Third People's Hospital of Yuhang District, Hangzhou, Zhejiang 311115, China. Electronic address: YAOcr2020@163.com.
  • Department of Medical Oncology, The Third People's Hospital of Yuhang District, Hangzhou, Zhejiang 311115, China.

Zitieren

APA

Yao, D., Zhou, H., & Chen, Q. (2026). Efficacy of prophylactic adoption of recombinant human granulocyte colony-stimulating factor in advanced lung cancer patients after chemotherapy. Tissue and Cell. https://doi.org/10.1016/j.tice.2025.103288

Vancouver

Yao D, Zhou H, Chen Q. Efficacy of prophylactic adoption of recombinant human granulocyte colony-stimulating factor in advanced lung cancer patients after chemotherapy. Tissue and Cell. 2026. doi:10.1016/j.tice.2025.103288

BibTeX
@article{Yao2026,
  author = {Yao, Dada and Zhou, Huaqiang and Chen, Qichen},
  title = {Efficacy of prophylactic adoption of recombinant human granulocyte colony-stimulating factor in advanced lung cancer patients after chemotherapy},
  journal = {Tissue and Cell},
  year = {2026},
  doi = {10.1016/j.tice.2025.103288}
}
Kostenlos starten →